The ZIP Code Gap: Why Geography Still Decides Cancer Outcomes

A cancer patient’s odds should not depend on their ZIP code. Too often, they still do — and the gap is not closing.

At Intersect, we talk often about the distance between where advanced medicine is concentrated and where patients actually live. I want to spend this post on what that distance costs people, because the numbers are stark, and because they point directly at the problem our platform was built to solve.

Start with cancer. Nationwide, cancer death rates in rural areas run roughly 14% higher than in urban areas, and the five-year survival rate across all cancers is about 8% lower in rural communities. That gap is not narrowing over time — it has been widening. And cancer is only one thread in a larger pattern. Rural Americans now live about 2.4 fewer years on average than their urban counterparts, and the rural–urban difference in overall age-adjusted death rates grew from 7% in 1999 to roughly 20% by 2019.

It Is Not Simply “Rural”

It is tempting to file this away as a rural problem. That framing is incomplete. The real divide is not rural versus urban — it is distance from concentrated specialty resources.

A patient in a remote county and a patient in an urban safety-net catchment area can run into the same wall: no molecular tumor board within reach, no genetic counselor on staff, no specialist who sees their particular cancer often enough to recognize the pattern quickly. Molecular tumor boards — the multidisciplinary teams that translate a tumor’s genomic profile into a treatment plan — exist almost exclusively at major academic cancer centers. Genetic counseling is unavailable in most community settings, and the country faces a shortage of thousands of genetic counselors, concentrated precisely where the need is greatest. Rural areas have roughly 65 primary care physicians per 100,000 residents, compared with about 105 per 100,000 in urban and suburban areas — and the specialist gap is far wider still.

The result is a two-tiered system. Patients at major centers receive genomically informed, guideline-concordant care as a matter of course. Patients elsewhere — rural and urban underserved alike — often do not.

The Consequences Are Measurable

This is not an abstraction. Studies of high-volume cancer centers show meaningfully better survival than community hospitals treating the same diagnoses — a difference attributable in significant part to access to precision medicine infrastructure, not to any deficit in the skill or commitment of community physicians.

That distinction matters. The community oncologist managing a non-small-cell lung cancer with an EGFR mutation is every bit as capable as a colleague at an academic center. What they often lack is the surrounding infrastructure: the tumor board to consult, the variant annotation pipeline, the structured decision support that a patient two hundred miles away receives by default. The gap is one of delivery, not talent.

What Intersect Is Building

This is the entire reason Intersect exists. Our hub-and-spoke model is designed to move the infrastructure — not merely the referral — to where the patient already is.

In the traditional model, a community hospital refers its most complex patients to a center of excellence, often never to see them again. The hub-and-spoke model instead connects academic medical centers and large integrated health systems (the hubs, or centers of excellence) to community oncology practices, Critical Access Hospitals, and urban safety-net settings (the spokes, the boots on the ground). Molecular tumor board workflow, pharmacogenomics, and genomic clinical decision support are delivered to the spoke — on a FHIR R6-native platform built to HL7 CodeX mCODE standards.

For the patient, that means specialty-grade genomic interpretation without a multi-hour drive. For the spoke hospital, it means staying part of the continuum of care — and retaining the associated revenue — rather than exporting its most complex cases. For the hub, it means extending its reach without building new physical infrastructure.

Bringing specialty-grade care closer to home would extend to underserved patients — wherever they live — the outcomes that well-resourced patients already take for granted. That is not a moonshot. It is a delivery problem. And delivery problems can be solved.